Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2022-04-12 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
《监事会议事规则》修正案
Governance Information Classification · 95% confidence The document is titled as a revision to the "Supervisory Board Meeting Rules" of a company, referencing various laws and regulations related to corporate governance and supervisory board functions. It details amendments to the rules governing the supervisory board's operations, rights, and meeting procedures. There is no indication of financial statements, audit opinions, earnings data, or shareholder voting results. The content focuses on governance structure and internal rules of the supervisory board, which aligns with governance information. The document length is substantial and contains detailed governance provisions, not just an announcement or summary. Therefore, the document best fits the category of Governance Information (CGR).
2022-04-12 Chinese
独立董事述职报告 （刘洪泉）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the year 2021" for a listed company. It details the independent director's attendance at board and committee meetings, opinions on various board resolutions including stock incentive plans, use of raised funds, audit firm reappointment, internal control evaluation, and other governance matters. The document is a detailed report of the independent director's duties, opinions, and oversight activities during the year. It is not a full annual report or financial statement, nor is it an announcement or proxy solicitation. It is a specialized governance-related report focusing on the independent director's role and opinions, which fits best under Board/Management Information (MANG) as it relates to board-level oversight and management governance activities. The document length and detail confirm it is a substantive report, not a brief announcement or certification.
2022-04-12 Chinese
总裁工作细则（2022年4月修订）
Governance Information Classification · 95% confidence The document is a detailed internal governance and management guideline titled '总裁工作细则' (President Work Rules) for Yifan Pharmaceutical Co., Ltd. It outlines the roles, responsibilities, appointment, and performance evaluation of senior management, especially the president and other executives. It references compliance with company law, securities law, stock exchange listing rules, and company articles of association. The content focuses on governance structure, management duties, reporting procedures, and internal control mechanisms rather than financial results or external reporting. It is not an announcement or a brief summary but a substantive governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing internal rules, board structure, and governance practices.
2022-04-12 Chinese
薪酬与考核委员会议事规则（2022年4月修订）
Remuneration Information Classification · 95% confidence The document is titled '薪酬与考核委员会议事规则' which translates to 'Rules of Procedure for the Remuneration and Assessment Committee'. It details the composition, responsibilities, meeting procedures, and duties of the Remuneration and Assessment Committee of the board of directors. The content focuses on governance aspects related to executive compensation and performance evaluation, including committee structure, meeting protocols, and confidentiality obligations. There is no financial data, earnings information, or report publication announcement. The document is a governance-related internal rules document concerning remuneration and assessment committee operations, which fits the Remuneration Information category.
2022-04-12 Chinese
投资管理制度(2022年4月修订)
Governance Information Classification · 95% confidence The document is titled '投资管理制度' (Investment Management System) and contains detailed internal rules and procedures regarding the company's investment decision-making authority, voting procedures, and governance related to investments. It references company laws, securities laws, stock exchange listing rules, and the company's articles of association. The content is focused on governance and internal control policies rather than financial results, audit opinions, or shareholder meeting materials. It does not present financial statements or earnings data, nor is it a brief announcement or a presentation. The document is a governance-related policy document detailing internal rules and procedures for investment management within the company. Therefore, it fits best under Governance Information (CGR). The document length is 2817 characters, which is consistent with a detailed policy document rather than a short announcement or a full annual report.
2022-04-12 Chinese
审计委员会议事规则（2022年4月修订）
Governance Information Classification · 95% confidence The document is titled "审计委员会议事规则" which translates to "Audit Committee Rules of Procedure". It details the composition, responsibilities, meeting procedures, and disclosure requirements of the company's audit committee. It references regulatory frameworks and internal governance but does not contain financial statements, audit opinions, or results of audits. It is a governance-related document outlining internal rules and procedures for the audit committee rather than an audit report or annual report. Therefore, it fits best under Governance Information (CGR). The document length (6322 characters) and content confirm it is a detailed governance document, not a brief announcement or a report publication notice.
2022-04-12 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.